Trial Profile

Phase I Dose Escalation Study of HQP1351 on Tyrosine Kinase Inhibitor (TKI) Resistant Patients with Chronic Myelogenous Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olverembatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions

Most Recent Events

18 Jun 2024 According to an Ascentage Pharma media release, the company announced that the the data of this trial have been released in posters at the 2024 European Hematology Association Hybrid Congress (EHA 2024), taking place in Madrid, Spain.
03 Nov 2022 According to an Ascentage Pharma media release, data from the trial will be presented at the 64th American Society of Hematology (ASH) Annual Meeting.
21 Sep 2022 Results presented in an Ascentage Pharma Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com